PA-824 is primarily used as an antimycobacterial agent, especially in the treatment of tuberculosis (TB). It shows potent activity against both drug-sensitive and multidrug-resistant (MDR) strains of Mycobacterium tuberculosis. The compound works through multiple mechanisms, including inhibition of cell wall mycolic acid synthesis and generation of reactive nitrogen species that damage bacterial components. It is a key component in new TB drug regimens, particularly for patients with limited treatment options due to resistance. PA-824 is often used in combination with other anti-TB drugs to enhance efficacy and reduce the risk of resistance development. Its ability to target dormant bacilli also makes it valuable in shortening the duration of TB therapy, including latent and active forms of the disease. Clinical development has focused on its oral bioavailability and favorable safety profile, supporting its use in extended treatment courses. It is being evaluated in advanced trials as part of novel regimens for pulmonary TB, with potential application in HIV-associated TB co-infections.